You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
賽升藥業(300485.SZ):子公司擬收購博奧生化100%股權
格隆匯 10-12 16:26

格隆匯 10 月 12日丨賽升藥業(300485.SZ)公佈,公司於2020年10月12日召開第三屆董事會第二十一次會議、第三屆監事會第二十一次會議,會議分別審議通過了《關於控股子公司收購股權的議案》,同意公司控股子公司瀋陽君元藥業有限公司(“君元藥業”或“丙方”)以現金方式收購長春博奧生化藥業有限公司(“博奧生化”或“目標公司”或“丁方”)100%股權。

近日,君元藥業與吉林省長白山醫藥保健品開發有限公司、王國林、長春博奧生化藥業有限公司、吉林省福祉康養有限公司簽署了《長春博奧生化藥業有限公司股權轉讓協議》,君元藥業擬以現金方式收購博奧生化100%股權。此次君元藥業受讓博奧生化100%股權包含的權益僅限於目標資產(藥品技術文件及檔案資料;生產及檢驗設備;商標和專利權),不含博奧生化的其他任何債權、債務。此次股權轉讓完成後,君元藥業將吸收合併博奧生化,博奧生化將目標資產併入君元藥業後,最終博奧生化予以註銷。

此次股權轉讓事項成功後,博奧生化的全部目標資產(包括但不限於藥品批號)將歸屬於君元藥業,該事項有利於豐富君元藥業藥品品種,完善產品結構,增加公司產品管線,打造公司未來商業生態整體格局。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account